SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-23-019043
Filing Date
2023-11-14
Accepted
2023-11-14 16:31:08
Documents
101
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q ibio-20230930x10q.htm   iXBRL 10-Q 1751820
2 EX-31.1 ibio-20230930xex31d1.htm EX-31.1 18446
3 EX-31.2 ibio-20230930xex31d2.htm EX-31.2 18792
4 EX-32.1 ibio-20230930xex32d1.htm EX-32.1 10601
5 EX-32.2 ibio-20230930xex32d2.htm EX-32.2 6717
6 GRAPHIC ibio-20230930x10q001.jpg GRAPHIC 64804
  Complete submission text file 0001558370-23-019043.txt   9801039

Data Files

Seq Description Document Type Size
7 EX-101.SCH ibio-20230930.xsd EX-101.SCH 104152
8 EX-101.CAL ibio-20230930_cal.xml EX-101.CAL 76853
9 EX-101.DEF ibio-20230930_def.xml EX-101.DEF 344622
10 EX-101.LAB ibio-20230930_lab.xml EX-101.LAB 630464
11 EX-101.PRE ibio-20230930_pre.xml EX-101.PRE 584522
95 EXTRACTED XBRL INSTANCE DOCUMENT ibio-20230930x10q_htm.xml XML 1561972
Mailing Address 600 MADISON AVENUE, SUITE 1601 NEW YORK NY 10022-1737
Business Address 600 MADISON AVENUE, SUITE 1601 NEW YORK NY 10022-1737 302 355-0650
iBio, Inc. (Filer) CIK: 0001420720 (see all company filings)

IRS No.: 262797813 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 10-Q | Act: 34 | File No.: 001-35023 | Film No.: 231407025
SIC: 2834 Pharmaceutical Preparations